

Form PTO-1449 (modified)

Atty. Docket No.

Serial N .

GOUD:031US

10/611,803

List of Patents and Publications for Applicant's

Applicant

Éric Gervais *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

July 1, 2003

Group:

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
PA	C1	Anke <i>et al.</i> , "Questions about drugs: how do pregnant women solve them?" <i>Pharm. World Sci.</i> , 26(6):254-259, 1994.
	C2	Czeizel and Dudas, "Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation," <i>New England J. Med.</i> , 327:1832-1835, 1992.
	C3	Einarson <i>et al.</i> , "Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling," <i>J. Psychiatry Neurosci.</i> , 26(1):44-48, 2001.
	C4	Koren and Pastuszak, "Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical and radiation exposure during the first trimester," <i>Teratology</i> , 41(6):657-661, 1990.
	C5	Matsui, "Drug compliance in pediatrics. Clinical and research issues," <i>Ped. Clin. N. Amer.</i> , 44(1):1-14, 1997.
	C6	Mazzotta <i>et al.</i> , "Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy," <i>J. Psychosom Obstet. Gynecol.</i> , 22(1):7-12, 2001.
	C7	Olesen <i>et al.</i> , "Do pregnant women report use of dispensed medications?" <i>Epidemiology</i> , 12(5):497-501, 2001.
PA	C8	Pastuszak <i>et al.</i> , "The effectiveness of preconceptional counseling on women's compliance with folic acid supplementation, maternal-fetal toxicology, A clinician's guide," 3 <sup>rd</sup> Edition, pp. 141-149, 2001.

25323587.1

EXAMINER:

DATE CONSIDERED:

6-8 2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

GOUD:031US

Serial No.

10/611,803

Applicant

Éric Gervais *et al.*

Filing Date:

July 1, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>pt</i>	C9	Pole <i>et al.</i> , "Drug labeling and risk perceptions of teratogenicity: A survey of pregnant Canadian women and their health professionals," <i>J. Clin. Pharmacol.</i> , 40:573-577, 2000.

25323587.1

EXAMINER: *[Signature]*DATE CONSIDERED: *6-6-2003*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket N .  
GOUD:031USSerial No.  
10/611,803

List of Patents and Publications for Applicant's

Applicant  
Éric Gervais *et al.*



INFORMATION DISCLOSURE STATEMENT

Filing Date:  
July 1, 2003Group:  
1615



(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,778,984	12/06/88	Marsik	128	738	1/30/87
	A2	5,443,288	8/22/95	Miles	283	2	7/25/94
	A3	5,457,895	10/17/95	Thompson <i>et al.</i>	34	296	10/01/93
	A4	5,531,230	7/02/96	Bell	128	842	7/14/95
	A5	5,836,890	11/17/98	Jackson	600	551	5/30/97
	A6	6,223,559	5/01/01	Coleman	63	1.13	7/20/99
	A7	6,226,564	5/01/01	Stuart	700	231	11/01/96
	A8	6,340,695	1/22/02	Gervais	514	345	6/21/01

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	2,050,054	3/20/92	Canada			
	B2	2,078,578	2/05/02	Canada			
	B3	2,081,679	5/28/93	Canada			
	B4	2,280,279	2/14/00	Canada			
	B5	2,310,069	6/03/99	Canada			
	B6	2,321,991	9/02/99	Canada			
	B7	EP 1 149 572	10/31/01	Europe			
	B8	WO 2004/004694	1/15/04	PCT			
	B9	WO 97/48384	12/24/97	PCT			

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
GOUD:031USSerial No.  
10/611,803

List of Patents and Publications for Applicant's

Applicant  
Éric Gervais *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 1, 2003Group:  
1615U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>R</i>	C10	Bishai <i>et al.</i> , "The efficacy and safety of Diclectin (R) (doxylamine/pyridoxine) for nausea and vomiting of pregnancy," <i>Today's Therapeutic Trends</i> , 17(2):167-179, 1999.
<i>R</i>	C11	Muno, "Broadening utility of tablet and capsule imprints," <i>Journal of Pharmacy Practice</i> , 13(2):130-140, 2000.
<i>R</i>	C12	Pedersen, "Tablet tooling: design, maintenance and troubleshooting," <i>Pharmaceutical Technology Europe</i> , 11(2):22-28, 1999.

25384711.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKET NO. <b>AAML/11621.35</b>	SERIAL NO. 10/611,803
LIST OF REFERENCES CITED BY APPLICANT (Use separate sheets if necessary)		APPLICANT <b>GERVAIS, Éric et al</b>	
		FILING DATE July 1, 2003	GROUP 1615

## U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
<i>AS</i>	6,352,713	3/5/02	KIRSCHNER ET AL.	424	441	12/1/99

## FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		ORIFER. F., Prenatal Vitamin Supplement, Hoechst Marion Roussel, September 25, 1996.

Examiner <i>[Signature]</i>	Date considered <i>6-8-2006</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (modified)

Atty. Docket No.  
GOUD:031USSerial No.  
10/611,803

List of Patents and Publications for Applicant's

Applicant  
Éric Gervais *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
July 1, 2003Group:  
1615U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>JA</i>	C13	"Continuing need to prevent exposures during pregnancy to medications known to cause birth defects," <i>CDC Media Relations Press Release</i> , August 17, 2001.
	C14	Daniel <i>et al.</i> , "Interpretations of a teratogen warning symbol," <i>Teratology</i> , 64(3):148-153, 2001.
	C15	Pearson, "Proposed switch of Acyclovir from prescription to over-the-counter status," <i>National Women's Health Network</i> , May 19, 1994.
<i>JA</i>	C16	Pole <i>et al.</i> , "Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals," <i>J. Clin. Pharmacol.</i> , 40(6):573-577, 2000.

25441920.1

EXAMINER: *[Signature]*

DATE CONSIDERED: 6-8-2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.